Intelligence Feed event · Equity · 2026-09-09

    CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric Label

    Question

    CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric Label

    Direct answer

    CRISPR Therapeutics reported that Q2 sales for blood disorder therapy Casgevy climbed 78% quarter-over-quarter to $76 million. The commercial ramp follows an FDA decision to expand Casgevy's indication to pediatric patients aged 2 and older, widening clinical adoption.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric Label”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-casgevy-q2-sales-surge-78-qoq-to-76m-on-pediatric-label-8a47b0

    EQUITY
    CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric Label
    CRISPR Therapeutics reported that Q2 sales for blood disorder therapy Casgevy climbed 78% quarter-over-quarter to $76 million. The commercial ramp follows an FDA decision to expand Casgevy's indication to pediatric patients aged 2 and older, widening clinical adoption.
    CRSPVRTX
    Impact
    71
    SEP 9
    SIG
    84%
    CRSPVRTX
    CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric Label
    CRISPR Therapeutics reported that Q2 sales for blood disorder therapy Casgevy climbed 78% quarter-over-quarter to $76 million. The commercial ramp follows an FDA decision to expand Casgevy's indication to pediatric patients aged 2 and older, widening clinical adoption.
    → Accelerated commercial ramp of Casgevy to $76 million quarterly revenue directly improves CRSP cash-burn trajectory and biotech valuation benchmarks.
    Impact
    CRISPR Therapeutics reported that Q2 sales for blood disorder therapy Casgevy climbed 78% quarter-over-quarter to $76 million. The commercial ramp follows an FDA decision to expand Casgevy's indication to pediatric patients aged 2 and older, widening clinical adoption.
    Affected
    CRSPVRTX
    Transmission
    Accelerated commercial ramp of Casgevy to $76 million quarterly revenue directly improves CRSP cash-burn trajectory and biotech valuation benchmarks.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPbiotechnology cash burn reduction from 78% QoQ commercial product growthUp1-4wCasgevy revenue grew 78% QoQ to $76M following FDA pediatric label approval.
    VRTXcommercial collaboration revenue recognition for Casgevy partnerUp1-4wVertex is the co-development and commercialization partner for Casgevy.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month